Nancy Lee, MD - ASTRO

More documents

Recommendations

Info

• Hi Historical t i l ddata t Outline • Toxicity as a result of non-surgical treatment • Use of IMRT for oropharyngeal cancer • Emergence of HPV related tumors
Page 1: Head and Neck II: Oropharynx, Laryn
Page 5 and 6: MR staging also T3N0.
Page 7 and 8: CA. OF THE OROPHARYNX INCIDENCE OF
Page 9 and 10: Oropharyngeal CA:Treatment Volume (
Page 11 and 12: RTOG 73-03 RT + Surgery for Head &
Page 13 and 14: RTOG 73-03 Oral Cavity and Orophary
Page 15 and 16: Surgery vs. Chemoradiotherapy Soo e
Page 17 and 18: BOT SCC of Oropharynx Parsons. Canc
Page 19 and 20: CA. OF THE TONSILLAR REGION SURVIVA
Page 21 and 22: CARCINOMA OF THE TONSIL 5 YEAR CAUS
Page 23 and 24: BASE OF TONGUE IMPLANTS Contraindic
Page 25 and 26: BASE OF TONGUE IMPLANTS Dose to the
Page 27 and 28: Tans-Tasman Radiation Oncology Grou
Page 29: RTOG 90-03 PHASE III STUDY OF ALTER
Page 33 and 34: RTOG 99-14 Phase II Trial of Concom
Page 35 and 36: RTOG 0129 Phase III Trial of Concur
Page 37 and 38: French Trial: Oropharyngeal CA (Den
Page 39 and 40: Intergroup Trial Adelstein Adelstei
Page 41 and 42: Meta-Analysis: Chemo (Pignon et al.
Page 43 and 44: Denis et al. IJROBP 55:93, 2003
Page 45 and 46: • Randomized, N=240 German Trial
Page 47 and 48: Chemoradiotherapy: Late FT Dependen
Page 49 and 50: An example of patient with late eff
Page 51 and 52: RTOG 0022 Phase I/II Study of Confo
Page 53 and 54:
Background • IMRT in the treatmen
Page 55 and 56:
Treatment Modality • Chemotherapy
Page 57 and 58:
Regional Control 3-year 94.3% 5-yea
Page 59 and 60:
OS, DMFS and Statistics OS : 3 year
Page 61 and 62:
• Xerostomia ≥ grade 2 Toxiciti
Page 63 and 64:
RL/LL H&N + LAN: Dose Distribution
Page 69 and 70:
IMRT vs sCo Conventional e to a RT
Page 71 and 72:
Phase III trial (GORTEC 2004-01) St
Page 73 and 74:
Conclusions • Excellent LRC is ac
Page 75 and 76:
Larynx Cancer
Page 77 and 78:
T1 Ca of the Glottis Radiotherapy D
Page 79 and 80:
Local Control (%) LOCAL CONTROL OF
Page 81 and 82:
Radiotherapy py Dose Fractionation
Page 83 and 84:
Control (%) ( Local LOCAL CONTROL O
Page 85 and 86:
Local Control (% %) LOCAL CONTROL F
Page 87 and 88:
Randomized trial on RT fraction siz
Page 89 and 90:
2006 ASTRO S T R A T I F Y RTOG 95-
Page 91 and 92:
S T R A T I F Y RTOG 91-11 Phase II
Page 93 and 94:
RTOG 91-11 VA CCRT RT 2 year Laryng
Page 95 and 96:
University of Chicago Stage IV of s
Page 97 and 98:
T3-4 T3 4 Glottic/Supraglottic Node
Page 99 and 100:
Stage T4 Carcinoma of the Glottis R
Page 101 and 102:
T3 T3-T4, T4 N+ Glottic Surpaglotti
Page 103 and 104:
VAH Laryngeal Carcinoma Study Laryn
Page 105 and 106:
VAH Laryngeal Carcinoma Study Salva
Page 107 and 108:
GETTEC Trial (J (J.M. M Richard Ri
Page 109 and 110:
Vocal Cord Fixation • Retrospecti
Page 111 and 112:
RTOG 91-11 Ph Phase III Trial T i l
Page 113 and 114:
RTOG 91-11 Distant Metastases 5 yr*
Page 115 and 116:
T4a N+ N Glottic Surpaglottic TTrea
Page 117 and 118:
For T4a tumors: BID fractionation?
Page 119 and 120:
Concurrent Chemoradiation with Alte
Page 121 and 122:
Chemoradiotherapy py • In the set
Page 123 and 124:
EORTC 24891 LARYNX PRESERVATION FOR
Page 125 and 126:
Hypopharynx yp p y
show all

Nancy Lee, MD - ASTRO

Create successful ePaper yourself

Delete template?

Save as template?